NEW YORK - McKesson Corporation (NYSE:MCK) reported third-quarter earnings and revenue that fell short of analyst expectations, sending shares down 4.3% in after-hours trading. The pharmaceutical distributor, however, raised its full-year earnings guidance.
McKesson posted adjusted earnings per share of $8.03 for the quarter ended December 31, 2024, missing the analyst consensus of $8.27. Revenue came in at $95.29 billion, up 18% YoY but below the $95.77 billion analysts had forecast.
Despite the earnings miss, McKesson raised and narrowed its fiscal 2025 adjusted EPS guidance to $32.55-$32.95, from the previous range of $32.40-$33.00. The midpoint of the new range, $32.75, is slightly above the analyst consensus of $32.67.
"McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%," said Brian Tyler, chief executive officer. "Our performance reflects the strength and momentum across the enterprise."
The company’s U.S. Pharmaceutical (TADAWUL:2070) segment, its largest business unit, saw revenues increase 19% to $87.1 billion, driven by increased prescription volumes and growth in the oncology platform.
McKesson also announced it had signed a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings, LLC, a provider of ophthalmology and retina management services.
The company returned $3.1 billion to shareholders in the first nine months of the fiscal year through share repurchases and dividends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.